Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Novacyt shares drop as France refuses to refund virus test

06/02/2020 | 06:53am EDT
FILE PHOTO: Outbreak of the coronavirus disease (COVID-19) in Paris

By Matthias Blamont and Sudip Kar-Gupta

High-flying shares in Novacyt dropped as much as 12% on Tuesday after the healthcare diagnostics firm said a French regulator had decided against approving the company's coronavirus test for reimbursement by the state.

France, like other countries, is betting on mass testing for COVID-19, the respiratory illness caused by the new coronavirus, as part of its strategy to emerge safely from the pandemic.

City laboratories in France that do the bulk of testing use kits that are approved by the Haute Autorite de Sante regulatory body for reimbursement via the social security system.

Novacyt said that although the regulator had not approved its test for reimbursement in France, it could still sell the product there for private patient testing.

Reimbursement was refused because Novacyt's test was developed with a single gene target, the company said. Other methods usually involve a DNA screening method known as generation sequencing, with samples that are larger and require lengthier reviews.

Novacyt has singled itself out with a test able to detect the new coronavirus in less than two hours. Standard testing, which also identifies other strains, takes up to a day.

Novacyt shares were down 9.8% at 3.51 euros at 1045 GMT, although they are still up by more than 2,000% since the start of this year, spurred by a wave of orders for its tests.

The company said on Tuesday it had total sales and confirmed orders worth 135 million euros for the product, with new deals in Zimbabwe and across Latin America.

As of May 14, Novacyt's test had been approved in more than 16 countries. The product has also received an Emergency Use Authorization (EUA) from the United States' Food and Drug Administration.

(Reporting by Sudip Kar-Gupta and Matthias Blamont; Editing by Barbara Lewis and Mark Potter)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
NOVACYT 2.55% 3.988 Real-time Quote.-59.31%
TELENOR ASA -0.24% 143.95 Real-time Quote.-1.34%
Latest news "Companies"
04:42pDEADLINE ALERT : Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against Romeo Power, Inc.
BU
04:21pUBISOFT ENTERTAINMENT  : New Werewolves Within and Mythic Quest Trailers Bring Horror and Comedy to Ubisoft Forward
PU
04:21pUBISOFT ENTERTAINMENT  : Far Cry 6 – Play as Legendary Villains With the Season Pass
PU
04:21pUBISOFT ENTERTAINMENT  : Assassin's Creed Valhalla's Road Ahead Unveiled, Second Year of Content Announced
PU
04:21pUBISOFT ENTERTAINMENT  : Mario + Rabbids Sparks of Hope Lands on the Nintendo Switch in 2022
PU
04:21pUBISOFT ENTERTAINMENT  : Just Dance 2022 Brings New Tracks to Level Up Your Dance Skills
PU
04:11pTom Clancy's Rainbow Six® Extraction Launches on September 16
BU
04:11pUBISOFT  : Reveals Rocksmith™+, the Future of Interactive Music Learning
BU
04:01pSANTA CLARA UNIVERSITY  : Class of 2021 Delights in Blended Celebration After Year of Uncertainty
BU
03:39pUBISOFT ENTERTAINMENT  : Riders Republic Launches on September 2, Register Now for Upcoming Betas
PU
Latest news "Companies"